CDKN2A and osteosarcoma: Lower expression of p16 in osteosarcoma patients was correlated with reduced response to primary chemotherapy [136], which, therefore, shows the importance of p16 as a prognostic and predictive biomarker and therapeutic target for cancer and metastasis.